| Document |
Document Title |
|
WO/2012/148926 |
Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are m...
|
|
WO/2012/149024 |
Materials and methods related to using multimeric DNA aptamers to treat demyelinating diseases are provided herein.
|
|
WO/2012/146724 |
The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, -NH-, or a direct bond; Y is -NH- or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical co...
|
|
WO/2012/147916 |
A compound represented by general formula [I-W], or pharmaceutically acceptable salt thereof. (The symbols that appear in the formula are as described in the description.)
|
|
WO/2012/147051 |
Food, particularly a beverage for human consumption, the ingestion of which enhances cognitive processes such as intelligence, memory, creativity and mood, and/or produces energizing effects. Said food is composed of a composition diluta...
|
|
WO/2012/147763 |
Provided is a compound, for example a compound represented by formula (I), or a pharmaceutically acceptable salt of the same, which has amyloid β production inhibitory activity, has, in particular, BACE1 inhibitor activity, and can be u...
|
|
WO/2012/148926 |
Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are m...
|
|
WO/2012/146371 |
The present invention relates to novel solid forms of agomelatine (I), specifically novel pharmaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that h...
|
|
WO/2012/149295 |
Pharmaceutical compositions comprising a compound of Formula I, e.g., an isolated form of anatabine or S-(-)-anatabine, or a pharmaceutically acceptable salt thereof, can be used to treat Autism Spectrum Disorders and seizure disorders.
|
|
WO/2012/147762 |
Provided is a compound which has amyloid β production inhibitory activity, especially a BACE-1 inhibitory effect and is useful as a therapeutic agent for diseases induced by the production, secretion or deposition of amyloid β protein....
|
|
WO/2012/149335 |
The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states ...
|
|
WO/2012/146052 |
A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and ...
|
|
WO/2012/149406 |
This document provides methods and materials involved in assessing and treating humans with LQTS or with a potential mutation in a KCNQ1 nucleic acid that encodes a Kv7.1 potassium channel subunit. For example, methods and materials for ...
|
|
WO/2012/146551 |
The present invention relates to ethynyl derivatives of formula I wherein X is N or C-R, wherein R is hydrogen or halogen; G is N or CH; with the proviso that maximum one of G or X can be nitrogen; R1 is phenyl or pyridinyl, which are op...
|
|
WO/2012/148225 |
The present invention relates to a sustained-release formulation comprising donepezil or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to a sustained-release pharmaceutical composition compr...
|
|
WO/2012/148308 |
The invention relates to novel alicyclic N,N'-substituted diazabicyclo[3.3.1]nonane derivatives of general formula (I) which act as allosteric AMPA receptor modulators, and to drugs based thereon which can be used for treating Alzheimer'...
|
|
WO/2012/146383 |
The invention relates to tapentadol (i) for use in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) for use in the treatment or the prevention of depression and/or of anxiety.
|
|
WO/2012/146552 |
The present invention relates to ethynyl derivatives of formula I wherein X is N or CH; G is N or CH; with the proviso that maximum one of X or G can be nitrogen; R1 is phenyl or pyridyl, which are optionally substituted by halogen, lowe...
|
|
WO/2012/149111 |
This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
|
|
WO/2012/147890 |
The present invention relates to a nitrogen-containing aromatic compound according to formula (I) that acts as an effective inhibitor of phosphodiesterase 10 (PDE 10). The present invention also relates to a pharmaceutical composition co...
|
|
WO/2012/146644 |
This invention relates to a salt of 3-[6-(2-methoxyethyl)-3-pyridinyl]-2-methyl-8-(4- morpholinyl)-imidazo[1,2-b]pyridazine, a phosphodiesterase 10 enzyme (PDE10) inhibitor, as well as to pharmaceutical compositions comprising the same, ...
|
|
WO/2012/149365 |
Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses of these antibodies, immunogenic peptides...
|
|
WO/2012/148225 |
The present invention relates to a sustained-release formulation comprising donepezil or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to a sustained-release pharmaceutical composition compr...
|
|
WO/2012/147933 |
The purpose of the present invention is to provide, in a simple and also inexpensive manner, a pharmaceutical composition which comprises a plurality of lysosomal enzymes and is effective in treating lysosomal storage disease caused by a...
|
|
WO/2012/145981 |
Chain compounds containing Adamantane or adamantane-like group, its stereoisomers, prodrugs, pharmaceutical salts, complex salt and solvate are provided. It comprises formula (I), where in S is a optionally substituted cyclic group, P is...
|
|
WO/2012/143117 |
The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
|
|
WO/2012/144854 |
The present invention relates to a pharmaceutical or food composition containing licochalcone A as an active ingredient for preventing, improving, or treating AMPK-related diseases, specifically, disorders involving lipid metabolism, hyp...
|
|
WO/2012/143143 |
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or ...
|
|
WO/2012/145234 |
The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need ...
|
|
WO/2012/144478 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof, which has an excellent 11β-hydroxysteroid dehydrogenase 1 inhibitory effect. (In the formula, R1 represents a...
|
|
WO/2012/143860 |
A method of ameliorating cognitive decline or a related condition, comprising oral administration of an effective amount of one or more compositions of mixed phospholipids and use of a mixed phospholipid composition in the manufacture of...
|
|
WO/2012/145651 |
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatri...
|
|
WO/2012/145651 |
Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatri...
|
|
WO/2012/145428 |
Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a...
|
|
WO/2012/145746 |
The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosu...
|
|
WO/2012/145581 |
Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders...
|
|
WO/2012/145428 |
Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a...
|
|
WO/2012/145737 |
Compounds of Formula 1 are described herein. These compounds may be administered to a patient for treatment of suffering from pain or other FAAH mediated conditions.
|
|
WO/2012/143337 |
The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other...
|
|
WO/2012/143116 |
The present invention relates to 4-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
|
|
WO/2012/143703 |
A compound of formula (I): or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R1, R2, R3, R4, R5, R6, X and m are as defined herein.
|
|
WO/2012/143526 |
The present invention relates to a compound of general formula (I), where: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN' group...
|
|
WO/2012/144661 |
A compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof is provided. The present invention is related to a compound represented by the formula (I). wherein R1a is substituted or unsubstituted alkyl or th...
|
|
WO/2012/143924 |
The present invention provides a synthetic polypeptide which is a random pentapolymer or a salt thereof, comprising alanine, glutamic acid, lysine, tyrosine and phenylalanine, useful for the treatment of autoimmune diseases and, in parti...
|
|
WO/2012/144972 |
|
|
WO/2012/144854 |
The present invention relates to a pharmaceutical or food composition containing licochalcone A as an active ingredient for preventing, improving, or treating AMPK-related diseases, specifically, disorders involving lipid metabolism, hyp...
|
|
WO/2012/143340 |
The present invention relates to ethynyl derivatives of formula (I), wherein, Y is N or C-R3;and R3 is hydrogen, methyl, halogen or nitrile; R1 is phenyl or pyridinyl, which are optionally substituted by halogen, lower alkyl or lower alk...
|
|
WO/2012/144938 |
The invention relates to medicine and concerns compositions (formulations) which can be, inter alia, in the form of biologically active additives and have the properties of hepatoprotectors and protectors against hepatic encephalopathy: ...
|
|
WO/2012/145098 |
A method of treating neuropathic pain in a subject is provided. The method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an A3AR agonist.
|
|
WO/2012/142666 |
The present invention relates generally to a method of treating or preventing conditions characterised by aberrant amine oxidase activity and agents useful for same. More particularly, the present invention relates to a method of treatin...
|
